- Home
- BNY vs FDMT Comparison
BNY vs FDMT Comparison
Compare BNY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- FDMT
- Stock Information
- Founded
- BNY 2001
- FDMT 2013
- Country
- BNY United States
- FDMT United States
- Employees
- BNY N/A
- FDMT N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- FDMT Health Care
- Exchange
- BNY Nasdaq
- FDMT Nasdaq
- Market Cap
- BNY 232.5M
- FDMT 192.2M
- IPO Year
- BNY N/A
- FDMT 2020
- Fundamental
- Price
- BNY $9.61
- FDMT $4.08
- Analyst Decision
- BNY
- FDMT Buy
- Analyst Count
- BNY 0
- FDMT 10
- Target Price
- BNY N/A
- FDMT $32.33
- AVG Volume (30 Days)
- BNY 52.7K
- FDMT 461.8K
- Earning Date
- BNY 01-01-0001
- FDMT 08-07-2025
- Dividend Yield
- BNY 3.93%
- FDMT N/A
- EPS Growth
- BNY N/A
- FDMT N/A
- EPS
- BNY N/A
- FDMT N/A
- Revenue
- BNY N/A
- FDMT $23,000.00
- Revenue This Year
- BNY N/A
- FDMT $13,048.65
- Revenue Next Year
- BNY N/A
- FDMT N/A
- P/E Ratio
- BNY N/A
- FDMT N/A
- Revenue Growth
- BNY N/A
- FDMT N/A
- 52 Week Low
- BNY $8.60
- FDMT $2.24
- 52 Week High
- BNY $10.80
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- BNY 42.94
- FDMT 52.91
- Support Level
- BNY $9.56
- FDMT $3.73
- Resistance Level
- BNY $9.69
- FDMT $4.62
- Average True Range (ATR)
- BNY 0.08
- FDMT 0.33
- MACD
- BNY 0.01
- FDMT -0.06
- Stochastic Oscillator
- BNY 26.32
- FDMT 25.55
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.